Data demonstrate efficacy of more flexible dose of regorafenib to relieve side-effects in mCRC patients

(European Society for Medical Oncology) some of the adverse events related to the use of regorafenib often limits its use in clinical practice. A study reported at the ESMO World Congress on Gastrointestinal Cancer 2019 suggests the usefulness of a more flexible dosing, which improves patients' quality of life without jeopardizing efficacy.